TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

Purpose: To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naive retinal angiomatous proliferation (RAP) and development of retinal pigment epithelium (RPE) atrophy. Methods: We retrospectively studied 17 treated eyes with RAP and 13 untreated fellow eyes. We assessed best-corrected visual acuity (BCVA) in logarithm of the minimal angle of resolution (logMAR) units and recorded the total number of injections for 12 months. Central macular thickness (CMT) and central choroidal thickness (CCT) were assessed by optical coherence tomography (OCT), and RPE atrophy extent in the macular area was assessed by fundus autofluorescence. Results: Average BCVA in eyes with RAP was 0.57 logMAR units (Snellen 20/74 or approximately 56.5 ETDRS letters) before treatment and significantly improved to 0.38 (Snellen 20/48 or approximately 66 ETDRS letters, P < 0.01) after 3 months and 0.32 (Snellen 20/42 or approximately 69 ETDRS letters, P < 0.01) after 12 months. Average CMT was 340 mu m before treatment and significantly reduced to 133 mm (P < 0.001) after 3 months and 130 mu m (P < 0.001) after 12 months. Average CCT was 147 mu m before treatment, 123 mu m (P < 0.01) after 3 months, and 131 mu m (P < 0.01) after 12 months. Average total number of injections was 7.2. Average area of RPE atrophy enlarged by 1.00 mm(2) in treated eyes compared with 0.34 mm(2) in fellow eyes (P < 0.01). The enlarged area of RPE atrophy was inversely correlated with central choroidal thickness after 12 months (rs = 20.49, P < 0.01) and positively correlated with the number of injections (rs = 0.58, P < 0.01). Conclusion: Treat-and-extend intravitreal therapy with aflibercept may be effective for improvement and stabilization of visual acuity and exudative change in eyes with RAP. However, choroidal thinning during the treatment regimen may accelerate enlargement of RPE atrophy.